Home >> Research Area >>Proteases/Proteasome>>HIV Protease>> HIV-1 integrase inhibitor 2

HIV-1 integrase inhibitor 2

HIV-1 integrase inhibitor CAS# 957890-42-5

HIV-1 integrase inhibitor 2

Catalog No. BCC1619----Order now to get a substantial discount!

Product Name & Size Price Stock
HIV-1 integrase inhibitor 2: 5mg $161 In Stock
HIV-1 integrase inhibitor 2: 10mg Please Inquire In Stock
HIV-1 integrase inhibitor 2: 20mg Please Inquire Please Inquire
HIV-1 integrase inhibitor 2: 50mg Please Inquire Please Inquire
HIV-1 integrase inhibitor 2: 100mg Please Inquire Please Inquire
HIV-1 integrase inhibitor 2: 200mg Please Inquire Please Inquire
HIV-1 integrase inhibitor 2: 500mg Please Inquire Please Inquire
HIV-1 integrase inhibitor 2: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of HIV-1 integrase inhibitor 2

Number of papers citing our products

Chemical structure

HIV-1 integrase inhibitor 2

3D structure

Chemical Properties of HIV-1 integrase inhibitor 2

Cas No. 957890-42-5 SDF Download SDF
PubChem ID 24800940 Appearance Powder
Formula C21H20ClNO2 M.Wt 353.84
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (282.61 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-(6-chloro-2-methyl-4-phenylquinolin-3-yl)pentanoic acid
SMILES CCCC(C1=C(N=C2C=CC(=CC2=C1C3=CC=CC=C3)Cl)C)C(=O)O
Standard InChIKey XRPUJSGGRFQZPJ-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H20ClNO2/c1-3-7-16(21(24)25)19-13(2)23-18-11-10-15(22)12-17(18)20(19)14-8-5-4-6-9-14/h4-6,8-12,16H,3,7H2,1-2H3,(H,24,25)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of HIV-1 integrase inhibitor 2

DescriptionHIV-1 integrase inhibitor 2 is an inhibitor of HIV-1 integrase used in the treatment of human immunodeficiency virus (HIV) infection

HIV-1 integrase inhibitor 2 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

HIV-1 integrase inhibitor 2 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of HIV-1 integrase inhibitor 2

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8261 mL 14.1307 mL 28.2614 mL 56.5227 mL 70.6534 mL
5 mM 0.5652 mL 2.8261 mL 5.6523 mL 11.3045 mL 14.1307 mL
10 mM 0.2826 mL 1.4131 mL 2.8261 mL 5.6523 mL 7.0653 mL
50 mM 0.0565 mL 0.2826 mL 0.5652 mL 1.1305 mL 1.4131 mL
100 mM 0.0283 mL 0.1413 mL 0.2826 mL 0.5652 mL 0.7065 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on HIV-1 integrase inhibitor 2

The human immunodeficiency virus (HIV) is the causative agent for the acquired immunodeficiency syndrome (AIDS), then HIV integrase is an attractive target for new anti-HIV drugs. HIV-1 integrase inhibitor is useful for anti-HIV, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome.
In vitro: On the basis of the available information, the authors synthesized several close analogs and discovered three new compounds with increased activity in vitro and in cell culture, thereby achieving an approximately tenfold increase of activity in AlphaScreen (IC50 = 1.37 ± 0.36 μM) and a nearly 20-fold increase in antiviral activity (EC50 = 2.35 ± 0.28 μM) for the most active compound, HIV-1 integrase inhibitor 2. The inter¬action of LEDGF/p75 with neither JPO2 nor PogZ (cellular bind¬ing partners of LEDGF/p7527–29) was inhibited, suggesting binding of the compound to integrase and not to LEDGF/p75. HIV-1 integrase inhibitor 2 did not affect integrase-DNA binding and only weakly inhibited the catalytic activities of integrase. These findings point to a different mechanism of action than that observed for the strand-transfer inhibitors raltegravir and elvitegravir. No inhibitory activity of HIV-1 integrase inhibitor 2 was detected against HIV-1 reverse transcriptase [1].
In vivo: Currently no in-vivo data available.
Clinical trial: Currently no clinical data available.
Reference:
[1] Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, De Maeyer M, Chaltin P, Debyser Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol. 2010;6(6):442-8.

Featured Products
New Products
 

References on HIV-1 integrase inhibitor 2

Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-buten oic acid as HIV-1 integrase inhibitor.[Pubmed:19556126]

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4806-9.

Ethyl [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl]-4-hydroxy-2-oxo-3-buteno ate 1 and [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-buten oic acid 2 were synthesized as potential HIV-1 integrase inhibitors and evaluated for their enzymatic and antiviral activity, acidic compound 2 being more potent than ester compound 1. X-ray diffraction analyses and theoretical calculations show that the diketoacid chain of compound 2 is preferentially coplanar with the quinolinone ring (dihedral angle of 0-30 degrees ). Docking studies suggest binding modes in agreement with structure-activity relationships.

Self-association and domains of interactions of an amphipathic helix peptide inhibitor of HIV-1 integrase assessed by analytical ultracentrifugation and NMR experiments in trifluoroethanol/H(2)O mixtures.[Pubmed:10567389]

J Biol Chem. 1999 Nov 26;274(48):34174-85.

EAA26 (VESMNEELKKIIAQVRAQAEHLKTAY) is a better inhibitor of human immunodeficiency virus, type 1, integrase than its parent Lys-159, reproducing the enzyme segment 147-175 with a nonpolar-polar/charged residue periodicity defined by four helical heptads (abcdefg) prone to collapse into a coiled-coil. Circular dichroism, nuclear magnetic resonance, sedimentation equilibrium, and chemical cross-linking were used to analyze EAA26 in various trifluoroethanol/H(2)O mixtures. In pure water the helix content is weak but increases regularly up to 50-60% trifluoroethanol. In contrast the multimerization follows a bell-shaped curve with monomers in pure water, tetramers at 10% trifluoroethanol, and dimers at 40% trifluoroethanol. All suggest that interhelical interactions between apolar side chains are required for the coiled-coil formation of EAA26 and subsist at medium trifluoroethanol concentration. The N(H) temperature coefficients measured by nuclear magnetic resonance show that at low trifluoroethanol concentration the amide groups buried in the hydrophobic interior of four alpha-helix bundles are weakly accessible to trifluoroethanol and are only weakly subject to its hydrogen bond strengthening effect. The increased accessibility of trifluoroethanol to buried amide groups at higher trifluoroethanol concentration entails the reduction of the hydrophobic interactions and the conversion of helix tetramers into helix dimers, the latter displaying a smaller hydrophobic interface. The better inhibitory activity of EAA26 compared with Lys-159 could arise from its better propensity to form a helix bundle structure with the biologically important helical part of the 147-175 segment in integrase.

1,4-Bis(5-(naphthalen-1-yl)thiophen-2-yl)naphthalene, a small molecule, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular Lens epithelium-derived growth factor.[Pubmed:24480521]

Chem Biol Interact. 2014 Apr 25;213:21-7.

Translocation of viral integrase (IN) into the nucleus is a critical precondition of integration during the life cycle of HIV, a causative agent of Acquired Immunodeficiency Syndromes (AIDS). As the first discovered cellular factor to interact with IN, Lens epithelium-derived growth factor (LEDGF/p75) plays an important role in the process of integration. Disruption of the LEDGF/p75-IN interaction has provided a great interest for anti-HIV agent discovery. In this work, we reported that one small molecular compound, 1,4-bis(5-(naphthalen-1-yl)thiophen-2-yl)naphthalene(Compound 15), potently inhibit the IN-LEDGF/p75 interaction and affect the HIV-1 IN nuclear distribution at 1 muM. The putative binding mode of Compound 15 was constructed by a molecular docking simulation to provide structural insights into the ligand-binding mechanism. Compound 15 suppressed viral replication by measuring p24 antigen production in HIV-1IIIB acute infected C8166 cells with EC50 value of 11.19 muM. Compound 15 might supply useful structural information for further anti-HIV agent discovery.

Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function.[Pubmed:21366258]

J Med Chem. 2011 Mar 24;54(6):1812-24.

2-Hydroxyisoquinoline-1,3(2H,4H)-dione was recently discovered as a scaffold for the inhibition of HIV-1 integrase and the ribonuclease H function of HIV-1 reverse transcriptase. First, we investigate its interaction with Mg(2+) and Mn(2+) using different spectroscopic techniques and report that 2-hydroxyisoquinoline-1,3(2H,4H)-dione forms a 1:1 complex with Mg(2+) but a 1:2 complex with Mn(2+). The complex formation requires enolization of the ligand. ESR spectroscopy shows a redox reaction between the ligand and Mn(2+) producing superoxide anions. Second, 2-hydroxyisoquinoline-1,3(2H,4H)-dione, its magnesium complex, and its 4-methyl and 2-hydroxy-4-methoxycarbonylisoquinoline-1,3(2H,4H)-diones were tested as inhibitors of HIV-1 integrase, reverse transcriptase ribonuclease H, and DNA polymerase functions. Their antiviral activities were evaluated and 2-hydroxy-4-methoxycarbonyl-isoquinoline-1,3(2H,4H)-dione was found to inhibit the viral replication of HIV-1 in MT-4 cells. Cross-resistance was measured for this compound on three different viral strains. Experimental data suggest that the antiviral activity of 2-hydroxy-4-methoxycarbonylisoquinoline-1,3(2H,4H)-dione is probably due to the RNase H inhibition.

Description

HIV-1 integrase inhibitor 2, in the treatment of human immunodeficiency virus (HIV) infection.

Keywords:

HIV-1 integrase inhibitor 2,957890-42-5,Natural Products,HIV Protease, buy HIV-1 integrase inhibitor 2 , HIV-1 integrase inhibitor 2 supplier , purchase HIV-1 integrase inhibitor 2 , HIV-1 integrase inhibitor 2 cost , HIV-1 integrase inhibitor 2 manufacturer , order HIV-1 integrase inhibitor 2 , high purity HIV-1 integrase inhibitor 2

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: